Seqirus USA Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$65.6M
Doctors Paid
15,410
Transactions
57,789
2024 Total
$16.7M
Payment Breakdown by Category
Research$64.2M (97.8%)
Food & Beverage$454,056 (0.7%)
Consulting$403,062 (0.6%)
Travel$142,101 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64.2M | 34,300 | 97.8% |
| Food and Beverage | $454,056 | 22,586 | 0.7% |
| Consulting Fee | $403,062 | 161 | 0.6% |
| Honoraria | $287,607 | 128 | 0.4% |
| Travel and Lodging | $142,101 | 180 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $108,605 | 29 | 0.2% |
| Grant | $20,000 | 1 | 0.0% |
| Education | $8,712 | 404 | 0.0% |
Payments by Type
Research
$64.2M
34,300 transactions
General
$1.4M
23,489 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | $14.9M | 0 | 12,030 |
| A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age | $6.9M | 0 | 208 |
| A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age | $6.9M | 0 | 12,551 |
| Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/?or H5N6 Influenza Vaccine in Adults | $5.6M | 0 | 220 |
| A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison With a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age | $5.5M | 0 | 228 |
| A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months | $3.7M | 0 | 153 |
| Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects | $3.5M | 1 | 492 |
| A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age | $3.0M | 0 | 341 |
| A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | $2.4M | 0 | 4,594 |
| Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults | $2.4M | 0 | 52 |
| Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | $2.3M | 2 | 2,659 |
| Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults | $2.3M | 2 | 333 |
| Adjuvanted influenza Vaccination and Morbidity and Mortaliy in US Nursing Homes | $2.1M | 0 | 8 |
| A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 Years of Age | $1.3M | 0 | 86 |
| This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine aTIV-1, Fluad, and versus an adjuvanted trivalent influenza vaccine aTIV-2, containing the alternate B strain | $1.0M | 0 | 103 |
| A Phase 2/3 Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Immunogenicity and Safety of the Adjuvanted SARS-CoV-2 Subunit Vaccine in Adults Aged 18 Years and Above | $137,740 | 0 | 31 |
| A PHASE 3 RANDOMIZED, OBSERVER-BLIND, MULTI-CENTER, CONTROLLED STUDY TO EVALUATE SAFETY, IMMUNOGENICITY, AND LOT-TO-LOT CONSISTENCY OF AN ADJUVANTED CELL CULTURE-DERIVED, H5N1 SUBUNIT INFLUENZA VIRUS VACCINE IN HEALTHY ADULT SUBJECTS 18 YEARS OF AGE | $83,437 | 0 | 9 |
| A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | $47,968 | 0 | 14 |
| A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above | $30,082 | 0 | 6 |
| A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Seasonal Cell Culture Influenza Trivalent TIVc or Quadrivalent QIVc Vaccine During Pregnancy | $30,063 | 0 | 2 |
| Vdg_Test Negative Study | $26,025 | 3 | 12 |
| A Phase III Randomized Observer-Blind Controlled Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults greater than or equal to 65 Years of Age | $16,000 | 0 | 8 |
| V13010 is A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | $10,200 | 0 | 2 |
| A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults 65 Years of Age | $9,600 | 0 | 6 |
| Clinical Study to Evaluate the Safety Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children | $8,417 | 1 | 127 |
| A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages 18 Years of Age | $8,000 | 0 | 2 |
| This is a study to assess the immune antibody response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine Seqirus QIV, in comparison with a US licensed 20162017 Quadrivalent Influenza Vaccine comparator QIV in a healthy pediatric population 6 months through 59 months of age. | $7,270 | 0 | 3 |
| Efficacy Study With QIVc in Pediatric Subjects | $6,625 | 1 | 5 |
| Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of Three Investigational Self-Amplifying Mrna/Lnp Influenza Virus Vaccines In Healthy Adults | $6,525 | 1 | 6 |
| Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects 2 to <18 Years of Age | $4,625 | 1 | 5 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Barbara Pahud, Md Mph Faap, MD MPH FAAP | Pediatric Infectious Diseases | Kansas City, MO | $4,863 | $0 |
| Amanda Dempsey, Md Phd, MD PHD | Pediatrics | Aurora, CO | $4,483 | $0 |
| Dr. Wilbur Chen, M.d, M.D | Infectious Disease | Baltimore, MD | $4,418 | $0 |
| Flor De Maria Munoz, Md, MD | Pediatric Infectious Diseases | Houston, TX | $4,216 | $0 |
| Eric Ball, M.d, M.D | Pediatrics | Lake Forest, CA | $4,058 | $0 |
| Santiago Lopez, M.d, M.D | Pediatric Infectious Diseases | Sioux Falls, SD | $4,000 | $0 |
| Dr. Jessica Peck, Dnp, Rn, Cpnp-Pc, DNP, RN, CPNP-PC | Pediatrics | League City, TX | $3,840 | $0 |
| Renuga Vivekanandan, Md, MD | Internal Medicine | Omaha, NE | $3,500 | $0 |
| Ms. Shirley Delair, M.d, M.D | Pediatric Infectious Diseases | Omaha, NE | $3,500 | $0 |
| Jesse Hackell, M.d, M.D | Pediatrics | Pomona, NY | $3,309 | $0 |
| Anita Chandra-Puri | Pediatrics | Chicago, IL | $3,216 | $0 |
| Boris Skurkovich, Md, MD | Pediatrics | Providence, RI | $3,100 | $0 |
| Dr. Michael Ison, M.d., M.s, M.D., M.S | Infectious Disease | Falls Church, VA | $2,975 | $0 |
| Mr. Paul Wisman, M.d, M.D | Pediatrics | Charlottesville, VA | $2,895 | $0 |
| Dr. Brandon Essink, M.d, M.D | Family Medicine | Creighton, NE | $2,790 | $0 |
| Daniel Finn, Md, MD | Pediatrics | Bardstown, KY | $2,682 | $0 |
| Dr. Robert Jeanfreau, M.d, M.D | Internal Medicine | Metairie, LA | $2,649 | $0 |
| Dr. Mohammad Madjid, Md, MD | Internal Medicine | Ventura, CA | $2,500 | $0 |
| Ann Moell, Md, MD | Family Medicine | Dayton, OH | $2,409 | $0 |
| Carole Moloney, Pnp, PNP | Pediatrics | Boston, MA | $2,380 | $0 |
| Dr. Olutola Adetona, M.d, M.D | Pediatric Emergency Medicine | San Antonio, TX | $2,172 | $0 |
| Dr. Laurence Chu, Md, MD | Otolaryngology | Austin, TX | $2,167 | $0 |
| John Richards, Md, MD | Family Medicine | South Jordan, UT | $2,164 | $0 |
| Tobias Pusch, M.d, M.D | Internal Medicine | Portland, OR | $2,109 | $0 |
| Darrell Herrington, Do, DO | Family Medicine | San Angelo, TX | $2,049 | $0 |
Ad
Top Products
- aH5N1c $4.4M
- Flucelvax $4.1M
Associated Products (10)
- aH5N1c $4.4M
- Flucelvax $4.1M
- QIV $3.0M
- Fluad $2.8M
- H5N1c $2.5M
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) $689,829
- FLUCELVAX QUADRIVALENT $388,788
- Fluvirin $267,310
- Fluad Quadrivalent $218,454
- aQIV $15,217
Payment Categories
- Food & Beverage $454,056
- Consulting $403,062
- Travel & Lodging $142,101
- Research $64.2M
About Seqirus USA Inc
Seqirus USA Inc has made $65.6M in payments to 15,410 healthcare providers, recorded across 57,789 transactions in the CMS Open Payments database. In 2024, the company paid $16.7M. The top product by payment volume is aH5N1c ($4.4M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Pediatrics ($495,563 to 4,992 doctors).
Payment categories include: Food & Beverage ($454,056), Consulting ($403,062), Research ($64.2M), Travel & Lodging ($142,101).
Seqirus USA Inc is associated with 10 products in the CMS Open Payments database, including aH5N1c, Flucelvax, and QIV.